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Minding the Aging Brain: Are We Ready for Personalized
Medicine?
Jason Karlawish, M.D. and Robert C. Green, M.D., M.P.H.
Department of Medicine and Medical Ethics and Health Policy and the Neurodegenerative
Disease Ethics and Policy Program, Perelman School of Medicine, University of Pennsylvania;
and the Division of Genetics, Department of Medicine, Brigham and Women’s Hospital and
Harvard Medical School, Boston
In this issue, Lineweaver and colleagues (1) report two remarkable findings: After
cognitively normal older adults learn they have the ε4 allele of the APOE gene that increases
the risk of developing Alzheimer’s disease, they perform worse on measures of subjective
and objective cognition compared with older adults who have this genotype but do not know
their genotype. Conversely, those who learn that they do not carry an ε4 allele perform
better on measures of subjective cognition compared with ε4-negative individuals who do
not know they are ε4 negative.
In a nested case-control design, the APOE genotype disclosure cohort was drawn from
cognitively and neurologically healthy adults whose average age was in the 70s and who
were enrolled in either a study of cognitive and neuroimaging changes associated with aging
or a study to assess the impact of genetic testing on mood and health behaviors. Fifteen of
the 74 participants (~20%) in this cohort chose not to learn their APOE genotype and were
enrolled in the nondisclosure cohort— a design that may have introduced confounding by
indication, as the participants who had less desire to learn their APOE genotype may also
have had less concern about their cognition. Disclosure, performed by a genetic counselor,
covered the necessary topics, and notably, no participant requested additional counseling.
Cognitive testing for the disclosure cohort was then performed some time after disclosure,
ranging from 1 to 24 months (mean of 8 months). The control cohort of participants who did
not know their APOE genotype was assembled from several memory center cohorts to
match the disclosed group on age, years of education, cognition, and APOE genotype
distribution.
APOE genotype alone was not associated with how participants rated their cognitive
abilities, but the interactions of genotype and disclosure were associated with self-ratings of
cognitive abilities. On the capacity scale of the Metamemory in Adulthood Questionnaire
and on three of the five scales of the Memory Functioning Questionnaire, persons who
learned that they were ε4 positive rated themselves lower than did ε4-positive individuals
who did not know their genotype. In contrast, people who knew they were ε4 negative rated
their memory abilities better than did ε4-negative individuals who did not know their
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genotype. These results suggest that knowledge of genotype, not the genotype itself, affects
subjective cognition.
Even more provocative was the association between knowledge of ε4-positive genotype and
performance on widely used measures of memory. Older adults who knew they were ε4
positive performed worse than those who were ε4 positive but did not know their genotype,
although this association was seen only on the measure of verbal memory (the logical
memory test) and not the measure of visual memory (the Rey-Osterrieth Complex Figure
Test).
What explains these results? They do not seem to be explained by depressive symptoms.
Other psychiatric features, such as anxiety and test-related distress, were not assessed in this
study, so it is not possible to infer whether they may explain the findings. Given that
disclosure of APOE genotype has been associated with mild, short-term test-related distress
(2, 3), future work should examine the role of this and other psychiatric features. The results
could potentially be explained by the content of disclosure and the affect of the researchers
who told participants about their genotype risk. How we frame risk has a substantial impact
on how people react to that information (the authors do not go into detail on this issue,
reporting only that “disclosure was performed by an experienced genetic counselor”). The
results may also reflect stereotype threat or lowered self-efficacy, in which being told that
you may perform poorly on a test can in turn lead to poor performance (4). This
phenomenon is well described in the educational testing literature and is often cited to
explain gender, ethnic, and racial differences in test performance (5).
Regardless of the explanation, the results of this study are concerning. They come at a time
when how we think about the nature of Alzheimer’s disease is radically transforming (6).
Genes and biomarkers are being used to stratify cognitively normal persons who have a risk,
over time, of developing clinically significant cognitive impairment. The operative word is
risk.
Among these measures, APOE genotype is a robust predictor of a person’s lifetime risk of
developing sporadic Alzheimer’s disease. In an era when hundreds of thousands of
individuals have learned about their genetic risk factors for common complex disorders,
including their APOE genotype (7), through consumer genomics companies, it is concerning
that this knowledge alone may influence performance on cognitive tests.
Genetic tests are not the only measures that indicate risk among cognitively normal
individuals. About 30% of cognitively normal older adults are amyloid positive, and the
percentage is higher among persons who are ε4 positive (8). It is therefore entirely plausible
that a substantial portion of the ε4-positive individuals in the Lineweaver et al. study were
amyloid positive and therefore in the “preclinical” stage of Alzheimer’s disease. If severity
of preclinical disease is measured by cognitive performance, then did disclosure of APOE
worsen their disease? Moreover, amyloid-positive individuals are currently being recruited
(with disclosure of that status) for clinical trials in which they will receive medication
intended to delay the appearance of cognitive signs. If the awareness of positive amyloid
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status, like awareness of APOE status, influences neuropsychological testing—the primary
outcome measure in these studies—then the outcome could suffer unexpected bias.
The results from Lineweaver et al. need replication using a randomized and controlled
design. Such a design has been employed by the Risk Evaluation and Education for
Alzheimer’s Disease (REVEAL) study to show that APOE disclosure does not adversely
affect the mood and well-being of middle-aged adults with a family history of Alzheimer’s
dementia, but the REVEAL study did not assess effects of APOE genotype disclosure on
cognition (2). If the effect is replicated, then studies would also be warranted to test whether
interventions might mitigate this effect.
Alzheimer’s disease is not the only neuropsychiatric disorder being transformed by
biomarkers. The director of the National Institute of Mental Health has remarked that the
latest edition of DSM remains overly descriptive, and he argues that disease-associated
biomarkers should be the foundation for defining mental illness (9). Policy makers have
been carried along. Vice President Biden recently enthused that we should “imagine when
we are able to identify the biomarkers for mental illness” (10). As psychiatry and neurology
leap into the era of personalized medicine, the results of studies like this one show that we
must also examine how this new model of medicine and medical care will affect our
patients’ health and well-being. They also show how cognitive impairment in aging is not
simply the result of brain lesions, but a disruption in the homeostasis between the individual,
the brain, and the world the person lives in—or, in short, a disruption of the mind.

Acknowledgments
Dr. Karlawish has served on a scientific advisory board for Senior Bridge, Inc., and has received research support
as a coinvestigator on a project funded by GE Healthcare through a contract with Tufts University to investigate the
use of amyloid imaging in persons with mild cognitive impairment; he receives royalties from Johns Hopkins
University Press. Dr. Freedman has reviewed this editorial and found no evidence of influence from these
relationships.
Supported by a Robert Wood Johnson Investigator Award in Health Policy Research, the Marian S. Ware
Alzheimer’s Disease Program, and NIH grants AG01024, HG002213, HG005092, and AG027841.

References
1. Lineweaver TT, Bondi MW, Galasko D, Salmon DP. Effect of knowledge of APOE genotype on
subjective and objective memory performance in healthy older adults. Am J Psychiatry. 2014;
171:201–208. [PubMed: 24170170]
2. Green RC, Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Brown T, Eckert SL, Butson M,
Sadovnick AD, Quaid KA, Chen C, Cook Deegan R, Farrer LA. REVEAL Study Group: Disclosure
of APOE genotype for risk of Alzheimer’s disease. N Engl J Med. 2009; 361:245–254. [PubMed:
19605829]
3. Roberts JS, Christensen KD, Green RC. Using Alzheimer’s disease as a model for genetic risk
disclosure: implications for personal genomics. Clin Genet. 2011; 80:407–414. [PubMed:
21696382]
4. Inzlicht, M.; Schmader, T. Stereotype Threat: Theory, Process, and Application. New York: Oxford
University Press; 2011.
5. Steele CM, Aronson J. Stereotype threat and the intellectual test performance of African Americans.
J Pers Soc Psychol. 1995; 69:797–811. [PubMed: 7473032]

Am J Psychiatry. Author manuscript; available in PMC 2014 August 05.

Karlawish and Green

Page 4

6. Karlawish J. Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease.
Neurology. 2011; 77:1487–1493. [PubMed: 21917767]
7. Frueh FW, Greely HT, Green RC, Hogarth S, Siegel S. The future of direct-to-consumer clinical
genetic tests. Nat Rev Genet. 2011; 12:511–515. [PubMed: 21629275]
8. Fleisher AS, Chen K, Liu X, Ayutyanont N, Roontiva A, Thiyyagura P, Protas H, Joshi AD,
Sabbagh M, Sadowsky CH, Sperling RA, Clark CM, Mintun MA, Pontecorvo MJ, Coleman RE,
Doraiswamy PM, Johnson KA, Carpenter AP, Skovronsky DM, Reiman EM. Apolipoprotein E ε4
and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer
disease. Neurobiol Aging. 2013; 34:1–12. [PubMed: 22633529]
9. Insel, T. NIMH Director’s Blog: Transforming diagnosis. 2013 Apr 29. http://www.nimh.nih.gov/
about/director/2013/transforming diagnosis.shtml
10. LeBlanc S. “Remarkable” mental health care changes near, Biden says. Boston.com. 2013 Oct 23.
http://www.boston.com/2013/10/23/bgcom-biden/irH1vH2GUVVd0aJC9XLFaI/story.html.

Am J Psychiatry. Author manuscript; available in PMC 2014 August 05.

